Literature DB >> 8675972

Benzodiazepines for depression? A review of the literature.

T K Birkenhäger1, P Moleman, W A Nolen.   

Abstract

The English language literature on the use of benzodiazepines: in depressive disorders was reviewed. We selected double-blind random assignment studies in which benzodiazepines; were compared with reference drugs and/or placebo. Comparative studies with classical (non-triazolo) benzodiazepines in major depression show that these agents do not alleviate the core symptoms of depression, although they do have an effect on sleep and anxiety. Classical benzodiazepines show some efficacy in minor depression, but this conclusion could be related to efficacy in patients suffering from anxiety disorders rather than depression. Triazolo-benzodiazepines, mainly alprazolam, have been found to be effective in mild to moderate depression, although they turned out to be inferior to tricyclic antidepressants (TCAs) in patients with endogenous or melancholic depression. Furthermore it is questionable whether triazolo-benzodiazepines cause amelioration of the core symptoms of depression. With regard to combination therapy benzodiazepines may contribute to antidepressant response in the first weeks, because of a faster onset of effect than TCAs and/or because of effects on different symptoms. Beyond the first weeks of treatment combination therapy does not seem superior to monotherapy with TCAs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8675972     DOI: 10.1097/00004850-199510030-00008

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  17 in total

1.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

2.  Pathophysiology of depression: do we have any solid evidence of interest to clinicians?

Authors:  Gregor Hasler
Journal:  World Psychiatry       Date:  2010-10       Impact factor: 49.548

3.  GABAergic control of depression-related brain states.

Authors:  Bernhard Luscher; Thomas Fuchs
Journal:  Adv Pharmacol       Date:  2015-01-14

Review 4.  Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population.

Authors:  Charlene Faye; Josephine C Mcgowan; Christine A Denny; Denis J David
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

Review 5.  Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options.

Authors:  Alastair J Flint
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 6.  Alprazolam for depression.

Authors:  Harm van Marwijk; Gideon Allick; Froukje Wegman; Arjan Bax; Ingrid I Riphagen
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

7.  Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.

Authors:  Boadie W Dunlop; Paula G Davis
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

8.  Incidence and determinants of long-term use of antidepressants.

Authors:  Welmoed E E Meijer; E R Heerdink; Hubert G M Leufkens; Ron M C Herings; Antoine C G Egberts; Willem A Nolen
Journal:  Eur J Clin Pharmacol       Date:  2004-02-19       Impact factor: 2.953

Review 9.  Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis.

Authors:  Corrado Barbui; Andrea Cipriani; Vikram Patel; José L Ayuso-Mateos; Mark van Ommeren
Journal:  Br J Psychiatry       Date:  2011-01       Impact factor: 9.319

Review 10.  Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.

Authors:  Autumn Walkery; Lauren D Leader; Emily Cooke; Amy VandenBerg
Journal:  Drug Des Devel Ther       Date:  2021-07-09       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.